BioLineRx Ltd. BLRX Stock
BioLineRx Ltd. Price Chart
BioLineRx Ltd. BLRX Financial and Trading Overview
| BioLineRx Ltd. stock price | 3.22 USD |
| Previous Close | 1.77 USD |
| Open | 1.77 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.73 - 1.77 USD |
| 52 Week Range | 0.55 - 1.98 USD |
| Volume | 302.86K USD |
| Avg. Volume | 526.69K USD |
| Market Cap | 107.68M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 USD |
BLRX Valuation Measures
| Enterprise Value | 66.81M USD |
| Trailing P/E | N/A |
| Forward P/E | -175 |
| PEG Ratio (5 yr expected) | 0.12 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.777778 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.123 |
Trading Information
BioLineRx Ltd. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 34.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.98 USD |
| 52 Week Low | 0.55 USD |
| 50-Day Moving Average | 1.35 USD |
| 200-Day Moving Average | 0.93 USD |
BLRX Share Statistics
| Avg. Volume (3 month) | 526.69K USD |
| Avg. Daily Volume (10-Days) | 325.47K USD |
| Shares Outstanding | 61.53M |
| Float | 61.53M |
| Short Ratio | 2.94 |
| % Held by Insiders | 0% |
| % Held by Institutions | 10.89% |
| Shares Short | 1.92M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 3.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.83% |
| Return on Equity (ttm) | -62.77% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -31463000 USD |
| Net Income Avi to Common (ttm) | -32183000 USD |
| Diluted EPS (ttm) | -0.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 43.29M USD |
| Total Cash Per Share (mrq) | 0.7 USD |
| Total Debt (mrq) | 12.88M USD |
| Total Debt/Equity (mrq) | 32.93 USD |
| Current Ratio (mrq) | 3.681 |
| Book Value Per Share (mrq) | 0.63 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28670000 USD |
| Levered Free Cash Flow (ttm) | -17594124 USD |
Profile of BioLineRx Ltd.
| Country | United States |
| State | N/A |
| City | Modi’in |
| Address | Modi’in Technology Park |
| ZIP | 7177871 |
| Phone | 972 8 642 9100 |
| Website | https://www.biolinerx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 49 |
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
Q&A For BioLineRx Ltd. Stock
What is a current BLRX stock price?
BioLineRx Ltd. BLRX stock price today per share is 3.22 USD.
How to purchase BioLineRx Ltd. stock?
You can buy BLRX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioLineRx Ltd.?
The stock symbol or ticker of BioLineRx Ltd. is BLRX.
Which industry does the BioLineRx Ltd. company belong to?
The BioLineRx Ltd. industry is Biotechnology.
How many shares does BioLineRx Ltd. have in circulation?
The max supply of BioLineRx Ltd. shares is 3.72M.
What is BioLineRx Ltd. Price to Earnings Ratio (PE Ratio)?
BioLineRx Ltd. PE Ratio is now.
What was BioLineRx Ltd. earnings per share over the trailing 12 months (TTM)?
BioLineRx Ltd. EPS is -6 USD over the trailing 12 months.
Which sector does the BioLineRx Ltd. company belong to?
The BioLineRx Ltd. sector is Healthcare.
BioLineRx Ltd. BLRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 102.15 USD — |
-0.54
|
— — | 101.35 USD — | 102.39 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}